Purpose of review Endocannabinoids (anandamide and 2-arachidonoylgycerol) and related N-acylethanolamines (N-oleoylethanolamine) exhibit opposite effects in the control of appetite. The purpose of this review is to highlight the similarities and differences of three major lipid-signaling molecules by focusing on their mode of action and the proteins involved in the control of food intake and energy metabolism.
Introduction
Fifteen years have elapsed since the discovery by Devane et al. [1] of N-arachidonoylethanolamine, christened anandamide, as an endogenous ligand of the cannabinoid receptors. This discovery led to the elucidation of a whole signaling system which, in addition to the CB 1 and CB 2 cannabinoid receptors, comprises a set of enzymes involved either in the biosynthetic pathways or catabolism, as well as a putative endocannabinoid transporter protein [2] . Today, anandamide is part of a variety of cannabinoid receptor endogenous ligands, together with diverse N-acylethanolamines, arachidonoyl amino acids, monoacylglycerides, and even related ethers which have been identified in mammals and been shown to bind to the cannabinoid receptors [3] (Fig. 1) . The arrival on the drug market in Europe (but not in the USA) of the cannabinoid CB 1 receptor antagonist/inverse agonist rimonabant for the treatment of obese and overweight patients with associated cardiovascular disease risk factors (type 2 diabetes and dyslipidemia), highlights the physiological mechanisms by which endocannabinoids exert their effect on appetite regulation, feeding and energy expenditure [4 ] . The present review summarizes the recent data describing these mechanisms, focusing on the role of anandamide, 2-arachidonoylglycerol, and oleoylethanolamide which seem to be the principal regulators of food intake and energy metabolism among the endocannabinoids and related N-acylethanolamines.
Endocannabinoids: to be or not to be
Anandamide is one of the major N-acylethanolamines studied over the last 15 years. Its isolation from pig brain and identification as an endogenous ligand of the cannabinoid receptors launched the quest for detecting its presence in different biological organisms as well as the search for the identification of structurally related fatty acid derivatives in mammals. The abundance and chemical diversity of endogenous compounds sharing with anandamide the cannabinoid receptors or its synthesizing and catabolic pathways raised the following question: what is an endocannabinoid? To be consistent with other neurotransmission systems, an endocannabinoid in the strict sense is an endogenous compound able to activate the endocannabinoid receptors, which are to date the G-protein-coupled CB 1 and CB 2 cannabinoid receptors. There are, however, a large variety of affinities and activities amongst the so-called 'endocannabinoids' (Fig. 1) . Within these restrictive criteria, in this review, anandamide and 2-arachidonoylglycerol have been considered The structures of the endocannabinoids and related N-acylethanolamines and acylglycerolesters are shown. The affinity for the cannabinoid receptors and peroxisome proliferator activated receptors (PPARs) are also provided. Note that for the PPAR data, functional data (EC 50 ) are more often reported than affinity data (K i or IC 50 ). ARA-Ala, N-arachidonoylalanine; ARA-Gly, N-arachidonoylglycine; ARA-Ser, N-arachidonoylserine; DEA, N-docosotetraenoylethanolamine; HEA, N-homo-g-linolenoylethanolamine; NADA, N-arachidonoyldopamine; 2-OG, 2-oleoylglycerol; PEA, N-palmitoylethanolamine; 2-PG, 2-palmitoylgycerol; SEA, N-stearoylethanolamine.
as endocannabinoids, whereas N-oleoylethanolamine is referred to as 'related N-acylethanolamine'.
Even if the molecular targets mediating their physiological properties are different, however, related N-acylethanolamines and anandamide, and to a lesser extent 2-arachidonoylglycerol, share some biosynthetic and catabolic pathways. The diverse biosynthetic routes leading to anandamide and N-acylethanolamines are increasingly being characterized. One of these routes involves a calcium-dependent N-acyltransferase (NAT) activity synthesizing the N-acylphosphatidylethanolamine (NAPE) precursors which, upon transformation by a NAPE-specific phospholipase D, give rise to the N-acylethanolamines [5] . Although the enzyme responsible for this NAT activity in the brain awaits identification, a recent report [6 ] describes the identification of a calcium-independent NAT enzyme (iNAT) synthesizing anandamide and N-acylethanolamine precursors highly expressed in rat testis. The recent generation of NAPE phospholipase D knockout mice possessing similar anandamide levels compared with the wild-type mice suggests that this enzyme may not be the primary enzyme responsible for anandamide biosynthesis [7 ] . Accordingly, additional enzymatic routes have recently been proposed. For example, a serine hydrolase-catalyzed double-deacylation of NAPEs, to generate the corresponding glycerophospho-N-acylethanolamines, followed by a phosphodiesterase-mediated cleavage to generate N-acylethanolamines, has been described. In this pathway NAPEs are synthesized by the serine hydrolase a/b-hydrolase 4 (Abh4) [8 ] . Another possible pathway for anandamide biosynthesis involves the phospholipase C-catalyzed cleavage of NAPE to generate phosphoanandamide, which is subsequently dephosphorylated by phosphatases affording the endocannabinoid [9 ] . With respect to 2-arachidonoylglycerol synthesis, two sn-1 selective diacylglycerol lipases (sn-1-DAGLa and sn-1-DAGLb) are responsible for the synthesis of 2-arachidonoyl glycerol from sn-1-acyl-2-arachidonoylglycerol precursors [10] . These precursors are synthesized from phosphatidylinositol by phospholipase C. A suggested alternative route is the hydrolysis of phosphatidylinositol in 2-arachidonoyl-lysophosphatidylinositol (lysoPI) by a phospholipase A 1 . This compound would, in turn, be hydrolyzed by a lysophospholipase C resulting in 2-arachidonoylglycerol [11] . Of great relevance to the topic of this review is the fact that endocannabinoids and related N-acylethanolamines were detected and quantified in many tissues linked to food intake and control of energy metabolism, including the brain, liver, gastrointestinal tract, and adipose tissue [12 ] . Importantly, the levels of these lipidic mediators vary with nutritional status (e.g. anandamide and oleoylethanolamide in the gut) and with the appearance of obesity (e.g. anandamide and 2-arachidonoylglycerol plasma levels in obese patients; see below).
The first step of signal cessation of endocannabinoids (and related compounds) requires their passage through the cell membrane to reach their catabolic enzymes. The question of the presence of an anandamide, as well as N-acylethanolamines and 2-arachidonylglycerol, uptake is subject to debate. A decisive step seemed to be achieved with the identification, using a small azidoaffinity labeled inhibitor LY2318912, of a high-affinity and saturable binding site involved in the transport of endocannabinoids [13] . Some close analogues of this molecule, however, have also been found to inhibit several brain serine hydrolases, including the enzymes responsible for the inactivation of endocannabinoids, raising once again the question of the presence of an active uptake [14, 15] .
With regards to the endocannabinoid catabolic pathways, at least four enzymes are known to be involved in the termination of endocannabinoid signaling, namely and in order of their cloning, fatty acid amide hydrolase (nowadays termed FAAH-1) [16] , monoacylglycerol lipase [17, 18] , N-acylethanolamine acid amidase [19] , and a fatty acid amide hydrolase-2 (FAAH-2) [20 ] . Moreover, some biochemical and pharmacological evidence suggests that additional hydrolases may be able to regulate endocannabinoid tone [21] [22] [23] . Among these enzymes, the role of FAAH-1 in obesity has been investigated both in animal models and in humans.
Lymphocytes from obese leptin-deficient ob/ob mice showed decreased FAAH-1 activity and expression [24] . Leptin, through binding to its receptor and via activation of a STAT-3 signaling pathway, activates a CRE-like binding site on the FAAH-1 promoter. Such a decrease in FAAH-1 mRNA level was also observed in human obese patients [25] . Indeed, adipose tissue FAAH-1 mRNA levels were strongly decreased in obese women patients (average BMI of 38) compared with lean controls (BMI of 23.5). By contrast, plasma anandamide and 2-arachidonoylglycerol levels were found to be increased in obese patients. None of these parameters were affected by a 5% weight loss. Interestingly, visceral fat accumulation seems to be a key event in the dysregulation of the peripheral endocannabinoid system. Circulating 2-arachidonoylglycerol levels are correlated with visceral fat mass, whereas in visceral adipose tissue CB1 and FAAH expression are negatively correlated to visceral fat mass [26 ] .
A single nucleotide polymorphism (cytosine 385 ! adenosine) of the FAAH-1 gene has been reported [27] .
To investigate a potential relationship between the FAAH cDNA 385 A/A (P129T) polymorphism and overweight disorders, a study involving 2667 patients was conducted and led to a strong correlation between the FAAH 385A/385A genotype and overweight/obesity. This effect was observed in both Caucasian and African-American populations but, interestingly, the Pro129Thr mutation was not associated with weight disorders in the Asian patients. The median BMI was significantly higher in the FAAH 385A/385A homozygous group than in the heterozygous and wild-type groups (P < 0.0001) [28] . In a Danish study involving a population-based cohort of 5801 white patients, however, the Pro129Thr variant of FAAH was not found to be associated with any fat accumulation phenotype [29] . Recently, Aberle and coworkers [30 ] observed in obese and dyslipidaemic patients exhibiting the Pro129Thr FAAH mutation an enhanced decrease in triglycerides and total cholesterol during a 6-weeks low-fat diet compared with the wild-type individuals. The reasons for such differences, however, are yet to be identified and understood.
The cannabinoid CB 1 receptor
The appetite-stimulating properties of cannabis preparations as well as of D 9 -tetrahydrocannabinol have been known for a long time (the so-called 'munchies'), even if the molecular mechanisms of these actions were only recently elucidated and continue to be investigated. Similarly, endocannabinoids such as anandamide and 2-arachidonoylglycerol [31, 32] have been reported to increase food intake and promote weight gain in rats via the activation of hypothalamic CB 1 cannabinoid receptors [33] . Indeed, mice deficient in this receptor eat less, are leaner and more resistant to diet-induced obesity compared with their wild-type littermates [34, 35] . In a similar fashion, cannabinoid antagonists/inverse agonists [36] [37] [38] [39] [40] [41] [42] reduce food intake and body weight both in animal models and in humans. Rimonabant-induced reduction in food intake is observed in lean as well as in genetically and diet-induced obese animals [43, 44] . Although a rapid development of tolerance to the rimonabant anorectic effect has been observed, the effect on body weight was found to be more sustained over time. Following treatment discontinuation, however, the body weight returns to the levels of the untreated animals [45, 46] . Besides the selectivity of rimonabant, its absence of effect in mice lacking the CB 1 receptor confirmed the CB 1 -mediated mechanism of action and the pivotal role of the endocannabinoid system in regulating food intake [34, 35, 37] . In fact, besides the effect on body weight, the adjustments of the glycaemic and lipid parameters as well as reduction in the visceral fat mass are important hallmarks of rimonabant administration in rodents [37,47 ,48] . In addition, blockade of the CB 1 cannabinoid receptor was recently shown to reduce the obesity-associated hepatic steatosis in a rodent model [47 ] . In humans, the results from clinical studies using rimonabant in treating the metabolic syndrome (RIO studies) have been published [49] [50] [51] [52] and there was found to be a reduction in body weight, a decrease in waist circumference (a sign of decreased visceral fat mass) and improvements in lipid and glucose profiles. Note that, similarly to the results for rodents, body weight and waist circumference returned to the levels of untreated patients following treatment discontinuation [51] . Extensive reviews on the therapeutic outcome of rimonabant have recently been published [53] [54] [55] 56 ].
One of the key features is that the weight loss is the consequence of the blockade of the endocannabinoid system, both at a central and a peripheral level. Resulting from activation of the endocannabinoid system at the central level, there is an enhancement in food intake and a decrease in satiety. A number of interactions between the endocannabinoid system and orexigenic and anorexigenic neuropeptides have been described that could explain part of the impact of this system on food intake [34, 36, 57] (Table 1 [ [47 ,72] , the gut [73] , the pancreas [74] [75] [76] [77] , the brain [31] , and skeletal muscles [78 ,79 ] . CART The peptide product of CART is a tonically active anorectic mediator CART is a downstram mediator of AEA orexigenic effects [36, 69] The mediator, its described actions on food intake, and reported interactions with the endocannabinoid system are listed. AEA, anandamide; 2-AG, 2-arachidonoylglycerol; CART, cocaine and amphetamine-related transcript; CB 1 cannabinoid receptor 1; NPY, neuropeptide Y; CRH, corticotropinreleasing hormone; a-MSH, a-melanocyte stimulating hormone.
During obesity, the peripheral endocannabinoid system is overactive (Fig. 2) The nuclear peroxisome proliferator-activated receptor a
Oleoylethanolamide, a mono cis-unsaturated and shorter analogue of anandamide, is an endogenous fatty acid derivative involved in feeding and body mass regulation. In food-deprived rats (24 h) oleoylethanolamide suppressed food intake upon refeeding, an effect shared with N-palmitoylethanolamine but not with anandamide or oleic acid. Unlike anandamide, oleoylethanolamide does not bind to cannabinoid receptors [82] , but like the endocannabinoid, it is metabolized by fatty acid amide hydrolase-1 [83] . Mice deficient for FAAH-1 exhibit a 40-fold increase in brain oleoylethanolamide levels [84] . The anorectic effect of oleoylethanolamide has a peripheral origin, since no effect on food intake was observed after direct administration of oleoylethanolamide in brain ventricles or following destruction of peripheral sensory fibers by capsaicin [85] . Levels of oleoylethanolamide in the intestine vary in relation to food consumption, since they are reduced during fasting and rise after refeeding; in other words, oleoylethanolamide levels give the opposite
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Figure 2 Overview of the endocannabinoid dysregulation in obesity
The endocannabinoid system is dysregulated in obese situations as described by the labels on the left. Obesity is characterized by an overall increase in endocannabinoid levels at central and peripheral sites (including circulating plasmatic levels). Upregulation of cannabinoid receptor CB 1 expression was also described in animal models in the liver [72] , skeletal muscle [78 ] , and visceral fat [46, 80] . Note that in humans decreased CB 1 receptor and fatty acid amide hydrolase (FAAH) expression was found in fat tissues [25, 26 ]. On the right side of the panel are given the effects on food intake and energy metabolism of activation of the endocannabinoid system. Both orexigenic -activation of the CB 1 receptor and anandamide (AEA) or 2-arachidonoylglycerol (2-AG) increased levels -and anorexigenic -action of oleoylethanolamide (OEA) through peroxisome proliferator activated receptor a and possibly GPR119 -pathways are shown. SREBP1c, sterol regulatory element binding protein 1c. pattern to that of anandamide level variations in response to food intake [73,86 ,87 ] . Oral administration of oleoylethanolamide gives a similar picture [88, 89] . The peroxisome proliferator-activated receptor a (PPARa) is one of the molecular targets of oleoylethanolamide [90, 91] , mediating satiety, body weight maintenance, and lipolysis. This nuclear receptor, involved in the regulation of lipid metabolism, has become, together with other PPARs an attractive drug target [92] to treat dyslipidemia, diabetes, obesity and metabolic syndrome [93, 94] . They are all ligand-activated transcription factors of the nuclear hormone receptor superfamily, sharing a high degree of structural homology, particularly in the DNA-binding domain and ligand and cofactor-binding domain, and act as lipid sensors [95] . Low-affinity PPARa activators such as fibrates are hypolipidemic agents that have been used as therapeutic agents for 40 years [96] . The interrelations between cannabinoids and PPARs were briefly reviewed by Sun et al. [97] ; not only oleoylethanolamide but also N-palmitoylethanolamine, anandamide, virodhamine and noladin ether, as well as synthetic unrelated cannabinoid agonists such as WIN-55,212-2, are able to activate, at least partially, mouse PPAR-a (Fig. 1) . In addition, other PPARs such as PPARg are the targets of both anandamide and 2-arachidonoylglycerol [98] but also of D
9
-tetrahydrocannabinol [99, 100] . A combination therapy with rimonabant, a CB 1 cannabinoid antagonist/inverse agonist, and oleoylethanolamide has been reported to enhance the feeding suppression effect both in normal rats and in genetically obese Zucker rats, resulting in body weight reduction. The serum and liver lipid levels were reduced by the treatment. A parallel amelioration in the hepatic steatosis, through the control of the gene expression of stearoyl coenzyme A desaturase 1, a key enzyme in lipid biosynthesis and triglycerides secretion, was also obtained [101 ] , an effect similar to what was described for N-stearoylethanolamine [102] . The effects of oleoylethanolamide on ghrelin [59] and on fatty acid translocase (FAT/CD36), an integral membrane protein facilitating the free fatty acid uptake into cells [103] , have also been described, although definitive answers for the responsible mechanisms remain to be defined.
The GPR119 receptor
GPR119, an orphan Ga(s) protein coupled receptor known to bind phospholipids [104] , has recently been 740 Functional foods The oxadiazoles PSN375963, PSN 632408, and AR231453 are GPR119 ligands [105 ,106 ]. The N-oleoylethanolamine derivatives are PPARa activators [107, 108 ] .
deorphanized. Indeed, N-oleoylethanolamide binds and activates GPR119. In addition, small molecules showing hypophagic properties like PSN375963 and PSN632408 (Fig. 3 [105 ,106 ,107,108 ] ) also act as GPR119 agonists, without affecting PPARa and transient receptor potential vanilloid type 1 (TRPV1) receptors, raising the possibility of an alternative mechanism explaining the satiety mediated by N-oleoylethanolamide A [105 ] . The expression and distribution of GPR119 in rodents is present in some abundance in the gastrointestinal tract, brain and pancreas. In this latter organ, GPR119 seems to be localized in the insulin-producing b-cells of the pancreatic islets where its mRNA levels were elevated in obese mice compared with lean animals [109] . Recently, Chu et al. [106 ] suggested that when using GPR119-deficient mice -which possess a diabetic phenotype -GPR119 functions as a glucose-dependent insulinotropic receptor and may be suitable for the development of potent, orally active, small-molecule antihyperglycaemic agents. Thus, selective GPR119 agonists would represent, alone or in combination with PPARa agonists or CB 1 receptor antagonists, valuable therapeutic agents for the treatment of obesity and metabolic syndrome.
Although two molecular targets -PPARa and GPR119, which provide a rationale for the N-oleoylethanolamide effects on food intake -have been identified, less is known about this N-acylethanolamine catabolism in the gastrointestinal tract. Indeed, the administration of a potent FAAH-1 inhibitor, URB597, did not potentiate the oleoylethanolamide-induced hypophagia [110] . In fact, inhibition of FAAH-1 in the rat failed to affect the intestinal levels of the N-acylethanolamines anandamide, N-palmitoylethanolamine and N-oleoylethanolamide. In addition oleoylethanolamide and N-palmitoylethanolamine levels in the intestine were only slightly enhanced in FAAH-1 -/-mice, and to a far lesser extent when compared with that observed in the brain and liver, suggesting that FAAH-1 does not play a key role in N-oleoylethanolamide-induced hypophagia. Further evidence in this regard is the fact that oleoylethanolamide produced a similar anorectic effect in wild-type and FAAH-1-deficient mice, suggesting that oleoylethanolamide metabolism in the intestine results from another enzyme. Candidate enzymes responsible for this activity are N-acylethanolamine acid amidase, which hydrolyses oleoylethanolamide and is expressed in the gastrointestinal tract [19] , as well as ceramidases, as recently suggested [111] . These data should open the way for further studies aiming at characterizing oleoylethanolamide hydrolysis in the gastrointestinal tract. We believe that inhibitors of oleoylethanolamide metabolism acting on the metabolism of oleoylethanolamide in the gastrointestinal tract could provide useful tools to regulate food intake.
Conclusion
All these recent findings are cause for considerable excitement in the drug discovery field. Antagonists of the CB 1 cannabinoid receptors are now well developed, as testified by the number of compounds in clinical trials [112] . Less is known on the potential of mimicking oleoylethanolamide actions by activating its targets, namely PPARa and GPR119. Furthermore, many patents and papers reported the search for mixed PPARa-g agonists or the use of combinations of the two agonists [113, 114] . Analogues of oleoylethanolamide, including N-octadecyl-N'-propylsulfamide (Fig. 3) have just been released and elicit both activation of PPARa and feeding suppressant properties [107] . It is important to note that one of the compounds, N-octadecylsulfamide, mimics the effects of oleoylethanolamide on body weight but fails to activate PPARa. High throughput screening on GPR119 revealed new synthetic ligands such as PSN375963 and PSN632408 with hypophagic properties [105 ] . Another recent example of a new GPR119 selective agonist is AR231453, a molecule that displays an enhanced glucose-dependent insulin release in vivo and improved oral glucose tolerance [106 ] .
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